Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
Public ClinicalTrials.gov record NCT04034927. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies how well olaparib with or without tremelimumab works in treating patients with ovarian, fallopian tube, or peritoneal cancer that has come back (recurrent). PARPs are proteins that help repair deoxyribonucleic acid (DNA) mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Immunotherapy with monoclonal antibodies, such as tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving olaparib and tremelimumab together may work better than olaparib alone in treating patients with ovarian, fallopian tube, or peritoneal cancer.
Study identification
- NCT ID
- NCT04034927
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 61 participants
Conditions and interventions
Conditions
- Fallopian Tube Endometrioid Tumor
- Fallopian Tube High Grade Serous Adenocarcinoma
- Malignant Ovarian Endometrioid Tumor
- Ovarian High Grade Serous Adenocarcinoma
- Platinum-Sensitive Fallopian Tube Carcinoma
- Platinum-Sensitive Ovarian Carcinoma
- Platinum-Sensitive Primary Peritoneal Carcinoma
- Primary Peritoneal High Grade Serous Adenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Fallopian Tube Endometrioid Adenocarcinoma
- Recurrent Ovarian Endometrioid Adenocarcinoma
- Recurrent Ovarian Serous Adenocarcinoma
- Recurrent Primary Peritoneal Carcinoma
- Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
Interventions
- Biospecimen Collection Procedure
- Computed Tomography Procedure
- Magnetic Resonance Imaging Procedure
- Olaparib Drug
- Tremelimumab Biological
Procedure · Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 4, 2019 (Actual)
- Primary completion
- Jul 31, 2021 (Actual)
- Completion
- Feb 21, 2027 (Estimated)
- Last update posted
- Aug 26, 2026
2019 – 2027
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange | California | 92868 | — |
| UCHealth University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| Hartford Hospital | Hartford | Connecticut | 06102 | — |
| Augusta University Medical Center | Augusta | Georgia | 30912 | — |
| University of Chicago Comprehensive Cancer Center | Chicago | Illinois | 60637 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| University of New Mexico Cancer Center | Albuquerque | New Mexico | 87106 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| UHHS-Chagrin Highlands Medical Center | Beachwood | Ohio | 44122 | — |
| Case Western Reserve University | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Women and Infants Hospital | Providence | Rhode Island | 02905 | — |
| UT MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Virginia Cancer Center | Charlottesville | Virginia | 22908 | — |
| VCU Massey Comprehensive Cancer Center | Richmond | Virginia | 23298 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04034927, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2026 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04034927 live on ClinicalTrials.gov.